60 Degrees Pharmaceuticals, Inc. filed a Form 8-K on November 20, 2026, disclosing receipt of a Nasdaq delisting determination letter dated November 19, 2026, and announcing a planned reverse stock split expected to become effective December 2, 2026.
Key Highlights
- Delisting notice received: Nasdaq's Listing Qualifications Department notified the company on November 19, 2026, that its bid price closed below $1.00 per share for 30 consecutive business days, from October 8, 2026 through November 18, 2026.
- Compliance period ineligibility: Because the company effected a 1-for-5 reverse stock split on February 24, 2025, and a 1-for-4 reverse stock split on January 20, 2026 (a cumulative ratio of 1-for-20), Nasdaq determined the company is not eligible for any standard compliance period under Listing Rule 5810(c)(3)(A)(iv).
- Hearing requested and fee paid: As of the filing date, the company requested a hearing before the Nasdaq Hearings Panel and paid the related $20,000 hearing fee, which stays suspension of trading pending the Panel's decision.
- Suspension deadline: Without a hearing request, securities would have been suspended at the opening of business on December 1, 2026; that suspension is now stayed pending the Panel's decision.
- Reverse stock split planned: The company confirmed with Nasdaq it will effect a reverse stock split of its issued and outstanding common stock, expected to become effective December 2, 2026, with trading on a split-adjusted basis under the existing symbol on The Nasdaq Capital Market.
- Split ratio not yet disclosed: The filing states that additional details, including the split ratio and treatment of fractional shares, will be disclosed prior to effectiveness.
60 Degrees Pharmaceuticals Responds to Nasdaq Bid Price Deficiency
According to the filing, 60 Degrees Pharmaceuticals (NASDAQ:SXTP) received a letter from Nasdaq's Listing Qualifications Department on November 19, 2026, citing a failure to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company's common stock closed below $1.00 per share for 30 consecutive business days spanning October 8, 2026 through November 18, 2026, triggering the notice.
The filing further disclosed that Nasdaq determined the company ineligible for the standard compliance cure period. The basis for that determination, according to the filing, is that the company had already effected two reverse stock splits within approximately one year: a 1-for-5 split on February 24, 2025, and a 1-for-4 split on January 20, 2026, producing a cumulative reverse stock split ratio of 1-for-20. Under Nasdaq Listing Rule 5810(c)(3)(A)(iv), this history renders the company ineligible for the compliance periods ordinarily available under Rule 5810(c)(3)(A). Nasdaq's staff accordingly determined to delist the company's securities.
The company disclosed it has already requested a hearing before the Nasdaq Hearings Panel and paid the $20,000 hearing fee, which stays both the suspension of trading and the filing of a Form 25-NSE pending the Panel's decision. The company also confirmed with Nasdaq that it plans to effect a reverse stock split expected to become effective December 2, 2026, under the existing trading symbol "SXTP" and a new CUSIP number. The filing states the company intends to present this reverse stock split to the Panel as part of its plan to regain compliance with the Bid Price Rule. The filing cautions that "there can be no assurance that the Panel will grant the Company's request for continued listing."
What Was Disclosed
60 Degrees Pharmaceuticals disclosed a Nasdaq delisting determination stemming from a bid price deficiency, its ineligibility for a standard compliance period due to prior reverse splits, the filing of a hearing request with a $20,000 fee, and a planned reverse stock split targeted for December 2, 2026.




Please wait processing your request...